氟马替尼二线治疗老年慢性髓性白血病的疗效及影响因素分析  

Analysis of the efficacy and factors affecting the second-line treatment of chronic myeloid leukemia in the elderly receiving flumatinib

作　　者：张司琪 孙晓星 杨世礼 葛洪峰 丰江舟 ZHANG Siqi;SUN Xiaoxing;YANG Shili;GE Hongfeng;FENG Jiangzhou(Department of Hematology,the Affiliated Bozhou Hospital of Anhui Medical University,Bozhou 236800,China)

机构地区：[1]安徽医科大学附属亳州医院血液内科,安徽省亳州市236800

出　　处：《实用老年医学》2025年第1期70-73,共4页Practical Geriatrics

基　　金：亳州市重点研发计划项目(bzzc2023061)。

摘　　要：目的分析氟马替尼二线治疗老年慢性髓性白血病(CML-CP)的疗效及影响因素。方法回顾性分析2020—2023年在我院接受氟马替尼作为二线药物治疗3个月以上的25例老年CML-CP病人的病例资料,评估氟马替尼治疗后的疗效、影响因素和安全性。结果25例病人中位随访24(2~48)个月,22例(88.0%)获得完全血液学缓解(CHR),10例(40.0%)获得主要分子学反应(MMR),中位PFS和OS分别为19.4个月和22.5个月。单因素分析结果显示,Sokal积分为影响病人MMR的因素,Sokal积分、伊马替尼治疗时间和治疗前耐药状态是获得完全细胞遗传学反应(CCyR)的影响因素。血液学不良反应发生率为28.0%(7/25),非血液学不良反应发生率为20.0%(5/25)。结论氟马替尼二线治疗老年CML-CP安全有效。Objective To analyze the efficacy and influencing factors of flumatinib as second-line treatment for elderly patients with chronic myeloid leukemia in chronic phase(CML-CP).Methods A retrospective study including 25 elderly CML-CP patients who received flumatinib as a second-line drug for more than 3 months in our hospital from 2020 to 2023 was conducted,and the efficacy and influencing factors were analyzed.Results A total of 25 patients who failed first-line imatinib treatment were collected,with a median follow-up of 24(2-48)months,22(88.0%)patients obtained complete hematological response(CHR)and 10(40.0%)patients obtained major molecular response(MMR).Univariate analysis showed that Sokal score was a factor influencing patients to obtain MMR;Sokal score,duration of imatinib treatment and pretreatment resistance status were influencing factors of CCyR.The median progression-free survival(PFS)and overall survival(OS)were 19.4 months and 22.5 months,respectively.The incidence rate of hematologic adverse events was 28.0%(7/25)and the incidence rate of non-hematologic adverse events was 20.0%(5/25).Conclusions Flumatinib is safe and effective in the second-line treatment of CML-CP in the elderly.

关 键 词：慢性髓性白血病 老年人 氟马替尼 疗效 

分 类 号：R557[医药卫生—血液循环系统疾病]